Trial Profile
A Two-Stage, Phase 1/2, Open-Label Study of the Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Valanafusp alfa (Primary)
- Indications Mucopolysaccharidosis I
- Focus Adverse reactions; Proof of concept
- Sponsors ArmaGen Technologies
- 16 Sep 2018 Status changed from active, no longer recruiting to completed.
- 10 Jul 2018 Results presented in an ArmaGen Technologies media release.
- 10 Jul 2018 According to an ArmaGen Technologies media release, 52-week results were published in Orphanet Journal of Rare Diseases.